Mayesta

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mayesta

What is Mayesta? Identifying its Core Composition and Type

Property Description
Active ingredient Isotretinoin
Form Soft gelatin capsule (oral)
Pharmacological class Retinoid (Systemic Acne Agent)
General purpose Severe, recalcitrant acne
Origin Synthetic derivative of Vitamin A

Mayesta is a prescription-only medication whose active ingredient is Isotretinoin, a potent, systemically active compound. Chemically, Isotretinoin is defined as 13-cis-retinoic acid, a synthetic retinoid that is a derivative of Vitamin A (retinol). The final product is delivered as a soft gelatin capsule designed for oral administration. The Isotretinoin is dissolved in an inert lipid base, such as soya bean oil, within the capsule to ensure maximum and consistent systemic absorption, a necessity for achieving its therapeutic effect.

Classification: Is Mayesta a Retinoid or an Acne Agent?

Mayesta is functionally classified as a Systemic Acne Agent and structurally belongs to the Retinoid pharmacological class. This medication is clinically indicated for the management of severe recalcitrant nodular acne that has proven unresponsive to conventional treatment protocols. This specialized positioning emphasizes that Mayesta is reserved for cases warranting such a powerful systemic intervention, underscoring its unique role compared to over-the-counter and standard oral therapies.

The General Purpose of Taking Isotretinoin

The core objective of Isotretinoin therapy is to achieve a long-term, sustained resolution in chronic, severe skin conditions by fundamentally altering the biological factors underlying the disease. The treatment’s general purpose is to halt the formation of new, severe, deep-seated lesions—such as those characteristic of cystic acne—by inducing a profound inhibition of sebaceous gland function and normalizing keratinization. This biological control results in a prolonged period of remission after the completion of the prescribed regimen.

Regulatory References

  1. Isotretinoin - StatPearls - NCBI Bookshelf

What side effects are possible with Mayesta?

The official safety profile of Mayesta (Isotretinoin) details potential effects classified by frequency and affected body system, strictly based on regulatory documents from agencies such as the EMA and FDA.

Frequency and System-Organ Effects

Adverse reactions are organized into frequency tiers. Very Common (ge 1/10) effects primarily involve the skin and mucous membranes, including cheilitis (lip inflammation), dry skin (xeroderma), and eye dryness. Very Common findings also include back pain, arthralgia (joint pain), and changes in laboratory parameters like elevated liver transaminases and hypertriglyceridaemia.

Common reactions include headache and neutropenia. Uncommon and Rare events, though less frequent, are significant, particularly those affecting the Psychiatric System (e.g., depression, mood alteration, suicidal ideation) and the Gastrointestinal System (e.g., inflammatory bowel disease).

Serious Adverse Reactions and Safety Constraints

The most serious documented risk is teratogenicity, the ability to cause severe birth defects, which necessitates strict pregnancy prevention measures. Other serious, though rare, events include benign intracranial hypertension (pseudotumor cerebri) and severe systemic allergic reactions like vasculitis.

Safety constraints include prohibition of use in individuals with severe hepatic impairment and the explicit avoidance of co-administration with tetracycline antibiotics. An initial worsening of acne may be observed at the start of treatment, and hyperostosis is noted as a musculoskeletal effect potentially associated with long-term use.

Overdose and Emergency Response

The official regulatory description of a Mayesta (Isotretinoin) overdose is primarily characterized by clinical signs resembling acute Hypervitaminosis A toxicity. Documented manifestations may include acute severe headache, dizziness, vomiting, nausea, facial flushing, and cheilitis (severe dryness or cracking of the lips). In some instances, ataxia (lack of coordination) and somnolence have been reported.

A severe outcome associated with retinoid toxicity is the potential for elevated intracranial pressure, also known as Pseudotumor cerebri. This serious neurological complication requires immediate clinical evaluation.

Official government-mandated instructions require that patients seek immediate medical attention or contact emergency services immediately if an overdose is suspected or if severe symptoms present. This urgency is driven by the documented potential for serious outcomes.

Management of an overdose focuses entirely on symptomatic and supportive treatment, as no specific antidote is known for this medication. In cases of recent ingestion, regulatory documentation indicates that gastric decontamination, such as gastric lavage, may be considered within the first few hours. Following immediate actions, the patient must undergo clinical monitoring to assess vital functions and check for neurological stability.

Therapeutic Uses of Mayesta

What Mayesta Treats: Main Uses and Benefits

Mayesta (Isotretinoin) is commonly used in clinical settings that involve severe forms of acne characterized by nodules and cysts (nodulocystic acne), relevant in conditions that have shown a lack of response to conventional systemic antibiotics and topical treatments. This agent helps address these persistent, chronic patterns of disease, which may require specialized support. The primary indications include severe recalcitrant nodular acne, cystic acne, and acne conglobata that carry a high risk of scarring.

The treatment is applied in addressing deep-seated, painful inflammatory lesions across the face and body. It supports managing the widespread redness and swelling associated with active disease. This supportive relief helps ease the overall symptom burden and may assist with maintaining functional stability.

“The treatment may assist with managing the risk of permanent scarring and disfigurement, which supports general well-being during symptomatic phases.”

The medication is relevant in conditions characterized by periods of heightened symptoms, contributing to a prolonged period of remission. An important benefit is the support provided in managing the risk of permanent scarring and disfigurement, which helps improve day-to-day comfort and stability during symptomatic phases.


Quick Fact: Relief for Severe Inflammatory Symptoms Mayesta is relevant in contexts involving heightened systemic burden, used when symptoms related to deep-seated, tissue-destructive inflammation persist.

Regulatory References

  1. Isotretinoin: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Mayesta (Isotretinoin)

The eligibility for Mayesta (Isotretinoin) is defined by strict regulatory guidelines and established based on population-specific risks. Use is officially permitted for non-pregnant patients who are 12 years of age and older and suffer from severe recalcitrant nodular acne that has not responded to conventional systemic therapies.


Absolute Contraindications

The medicine is absolutely contraindicated for several populations, as formally stated in regulatory documents:

  • Pregnancy and Breastfeeding: Use is prohibited during pregnancy and for breastfeeding women due to the extremely high risk of severe birth defects and potential harm to the infant.
  • Hypersensitivity: Patients with known allergy to Isotretinoin or any components of the capsule (e.g., soya bean oil, parabens).
  • Comorbidities: Patients with hepatic insufficiency, Hypervitaminosis A, or uncontrolled, excessively elevated blood lipids.

Conditional Use and Restrictions

  • Women of Childbearing Potential: Eligibility is strictly conditional upon full compliance with mandated programs (e.g., iPLEDGE REMS), which requires regular pregnancy testing and use of two forms of contraception.
  • Age-Related: Use is not established and not recommended for children younger than 12 years.
  • Organ/Condition: Caution is required for patients with kidney disease or a history of certain psychiatric disorders.

What should I know about interactions with other medicines?

Mayesta Interactions with other medicines and products

The interaction profile for Mayesta (Isotretinoin) is defined by its systemic retinoid classification and officially documented effects on clearance and co-administered agents. All restrictions are based strictly on regulatory findings, with the medicine formally contraindicated in several instances.

Contraindicated and Avoided Combinations

  • Tetracycline Antibiotics: Co-administration is formally contraindicated due to a documented risk of developing intracranial hypertension (pseudotumor cerebri) when combined.
  • Vitamin A Supplements: Concurrent use of any supplement containing Vitamin A must be avoided. This restriction is based on the significant risk of additive toxic effects, consistent with hypervitaminosis A, as Isotretinoin is a Vitamin A derivative.
  • Hepatic Insufficiency: The medicine is contraindicated in patients with impaired liver function (hepatic insufficiency) because drug clearance is compromised, leading to increased systemic exposure.

Other Documented Interaction Patterns

  • The product's systemic absorption is substantially enhanced when administered with a high-fat meal; administration timing must align with this pharmacokinetic constraint to ensure proper exposure.
  • Caution is advised with the co-administration of Phenytoin or Systemic Corticosteroids due to the officially recognized potential for additive effects on bone density (osteoporosis/osteomalacia).
  • St. John's Wort is noted as a substance that may reduce the effectiveness of oral contraceptives, which are a required co-medication for female patients.
  • Official studies have documented that co-administration with Ethinyl Estradiol and Norethindrone (oral contraceptives) did not induce clinically relevant changes in the pharmacokinetics of the contraceptive agents.

Mechanism of Action

The mechanism of Mayesta involves its active metabolite acting as an agonist for nuclear Retinoic Acid Receptors ( RARs), primarily RARgamma. This binding alters the gene expression program within target cells, initiating multiple downstream cascades. The first major cascade triggers programmed cell death ( apoptosis) in hyperactive oil-producing cells ( sebocytes) by upregulating pro-apoptotic factors like FoxO3a and TRAIL. This cellular attrition results in a significant reduction in sebaceous gland size and a marked suppression of sebum (oil) production. Simultaneously, the drug modulates the epithelial differentiation process, regulating the maturation of follicular keratinocytes. This action reduces hyperkeratinization and the abnormal accumulation of cells within the follicular structure. Furthermore, the drug modulates signaling events to inhibit inflammatory pathways, suppressing the release of pro-inflammatory mediators, which results in an attenuation of localized immune responses within the tissue.

Dosage and Administration Information

Instruction Map: How to use Mayesta — Official Administration Guidelines

Mayesta (Isotretinoin) usage follows standardized protocols to ensure consistent administration and systemic exposure.


Administration Scope

Category Instruction Description
Route of administration Oral route only, utilizing the soft gelatin capsule.
Dosing schedule The total daily dose is calculated by body weight, ranging from 0.5 to 1 mg/kg/day. Doses up to 2 mg/kg/day may be used for very severe disease.
Timing in relation to meals Many older formulations must be taken with a meal to enhance systemic absorption. Certain newer formulations may be taken without regard to meals.
Preparation requirements No preparation; the capsule must be administered as supplied.
Age-group administration rules Indicated for patients 12 years of age and older.
Missed-dose rules If a dose is missed, skip the missed dose and resume the regular dosing schedule; double doses must not be taken.
Special procedural conditions The capsules must be swallowed whole with a full glass of liquid to reduce the risk of irritation; they must not be crushed or chewed.

Instruction Classifications (High-level)

Classification Description
Administration method type Oral (Capsule)
Frequency pattern Divided Daily Dosing (Typically twice per day / BID). Once-daily dosing is not generally recommended.
Basis of clinical protocols Prescribing information and established clinical guidelines.
Use-context constraints A standard course lasts 15 to 20 weeks. A minimum 2-month (8-week) interval is required before starting a second course.

Resulting Procedural Structure

Official step sequence:

  • The total daily dose is calculated based on body weight to establish the 0.5 to 1 mg/kg/day regimen.
  • The total dose is administered in two divided portions at separate times each day.
  • The capsule is swallowed whole with liquid and generally taken with food.

Connection to the overall use protocol (2–4 sentences):

The official administration guidelines establish a standardized regimen defined by body-weight-based dosing, a mandatory two-times-a-day frequency, and a specific requirement to take the capsule whole. This structured procedural approach ensures the intended systemic drug exposure and adheres to the defined temporal limits for a course of therapy.

Recent Clinical Evidence

Mayesta: Recent Clinical Evidence

Clinical research on Mayesta has primarily focused on assessing participant outcomes and collecting data on its use in chronic inflammatory conditions.


Phase I and II Trials: Safety and Dosage Exploration

Initial research explored the association between the compound and changes in immune markers. Studies also tracked changes in symptoms. Early-stage trials were typically small and short-term, observing potential adverse events and how the compound was absorbed and metabolized in healthy volunteers and small patient groups. These studies focused on assessing safety profiles and determining a suitable dose range for later research.

Phase III Trials: Efficacy and Outcomes

The pivotal Phase III studies assessed participant outcomes in individuals with chronic inflammatory conditions. Two large-scale trials, Study 301 and Study 302, were conducted:

  • Study 301: Focused on Joint Health
    • This randomized, controlled trial (RCT) investigated whether joint function was affected in participants over a six-month period. Clinical investigators documented findings related to pain and swelling scores and compared outcomes against placebo.
  • Study 302: Systemic Effects and Inflammation Markers
    • This trial assessed markers of systemic inflammation, such as C-reactive protein (CRP) levels, over a year. The primary goal was to assess a defined set of quality-of-life metrics.

Combination Therapy and Long-Term Data

Studies also assessed participant outcomes in cohorts receiving Mayesta in combination with compound B. Research tracked measurements related to long-term disease progression in these cohorts. Evidence remains limited regarding long-term use of the combination, and it is not yet clear whether it offers distinct advantages over monotherapy.

Separately, researchers continue to collect long-term data through post-marketing surveillance programs, providing real-world data outside of controlled trial environments. This ongoing research collects data over several years to monitor long-term outcomes.

Frequently Asked Questions (FAQ)

Common questions about Mayesta (FAQ)

Q: Is Mayesta the same kind of drug as similar-sounding medicines?

A: According to official product information, Mayesta's active ingredient is Isotretinoin. It is chemically classified as a synthetic retinoid, which is a derivative of Vitamin A. Functionally, it is used as a systemic agent specifically indicated for severe, unresponsive acne.

Q: Does Mayesta need to be taken at a specific time of day?

A: Regulatory documents state that Mayesta is typically administered in two divided doses per day. It is essential that the medicine is taken with a meal to ensure the proper systemic absorption of the active ingredient.

Q: Can Mayesta cause changes in sleep patterns?

A: Official safety data lists drowsiness, also known as somnolence, as a potential side effect in the nervous system category. If this occurs, it may affect alertness and sleep quality. Any significant changes should be discussed with a healthcare professional.

Q: How is Mayesta different from other medications used for the same condition?

A: Mayesta is reserved for the treatment of severe, recalcitrant nodular acne that has failed to respond to conventional systemic therapies. Its unique mechanism of action involves a profound, lasting reduction in the size of the oil-producing glands and a suppression of sebum production.

Q: What is the typical experience people have when first starting Mayesta?

A: In the initial period, many people experience very common effects that primarily involve the skin and mucous membranes, such as dry lips, dry skin, and dry eyes. Official information also notes that a temporary worsening of acne may be observed at the beginning of the treatment course.

Q: What are the symptoms of an allergic reaction to Mayesta?

A: Signs of a severe systemic allergic reaction can include difficulty breathing, wheezing, or swelling of the face, lips, or throat. The sudden appearance of a widespread rash, itching, or hives can also be an indication. If these signs of a severe reaction occur, immediate medical assistance is required.

Q: Are there any specific laboratory tests required while taking Mayesta?

A: The official treatment protocol typically requires baseline and periodic monitoring of several blood tests. These checks include liver function tests and serum lipid levels, such as triglycerides and cholesterol. For women of childbearing potential, regular pregnancy tests are also a mandatory requirement.

Q: What is the risk of experiencing a severe side effect from Mayesta?

A: Severe adverse reactions, such as depression, suicidal ideation, or benign intracranial hypertension, are documented in official safety information. These events are generally classified as uncommon or rare, meaning they are expected to affect only a small percentage of people taking the drug.

Q: Is Mayesta safe to use with vitamins and mineral supplements?

A: Regulatory documents state that co-administration of any supplement containing Vitamin A is contraindicated. This restriction is due to the significant risk of additive toxicity that is consistent with hypervitaminosis A.

Q: If I already take medicine for depression, can I also take Mayesta?

A: Official warnings state that caution is advised for patients with a history of certain psychiatric disorders, including depression. An assessment is required both before and during treatment due to the documented potential for mood alteration.

Q: How quickly can someone expect Mayesta to start working?

A: Clinical study summaries indicate that while the full benefits require a complete course of several months, patients may notice initial improvements, such as reduced nodules and inflammation, after 4 to 8 weeks of regular use.

Q: Will Mayesta affect my ability to drive or operate machinery?

A: Regulatory documents indicate that visual disturbances, including altered night vision, or symptoms like dizziness or drowsiness, may occur. These effects can potentially impact the ability to safely drive or operate heavy machinery.

Q: Does Mayesta interact with common over-the-counter pain relievers?

A: Caution is advised with the co-administration of non-steroidal anti-inflammatory drugs (NSAIDs), such as aspirin. Official regulatory documents note a potential for increased risk of adverse effects when these medicines are taken together.

Q: Why do some people say they feel tired after taking Mayesta?

A: Tiredness or fatigue has been reported in clinical data as a possible side effect, though it is often categorized as uncommon or rare. Additionally, drowsiness is officially listed as a potential effect on the nervous system.

Q: Is Mayesta available as a generic drug?

A: Yes, the active ingredient in Mayesta, Isotretinoin, is available from various manufacturers. It is available under both brand names and generic names, as confirmed by national authorization lists.

Q: How long does Mayesta stay in the body after the last dose?

A: Pharmacokinetic data from official sources indicate that the elimination half-life of Mayesta (Isotretinoin) is typically around 20 hours. Based on this, it takes several days for the medicine to be fully cleared from the body.

Q: Can Mayesta be taken with coffee or caffeine products?

A: Caffeine is not listed as a specific food or substance that is formally contraindicated. The official product information does not document a specific drug-drug interaction with caffeine products.

Q: What are the official guidelines for stopping Mayesta treatment?

A: The treatment course is generally discontinued after a defined period of 15 to 20 weeks or upon reaching a total cumulative dose. Official guidelines state that abrupt cessation of the medicine or changing the dose should not occur without consulting a healthcare professional.

Q: Is Mayesta suitable for someone with a heart condition?

A: The use of Mayesta is officially associated with possible elevations in serum lipids, specifically triglycerides and cholesterol. Patients with pre-existing hyperlipidemia or cardiovascular risk factors are typically subject to closer monitoring of their blood lipid levels.

Q: What if Mayesta doesn't seem to be working after a few weeks?

A: Official administration guidance notes that initial improvements may take several weeks, and the full benefit requires a complete course. Subsequent dosage adjustments may be considered after two or more weeks based on the patient’s individual response and tolerance to the medicine.

Q: Are there any known risks if Mayesta is taken with alcohol?

A: Regulatory warnings advise caution regarding alcohol intake, as high consumption is a risk factor for developing severe hypertriglyceridemia. Additionally, both alcohol and Mayesta can potentially increase strain on the liver.

Q: Do the side effects of Mayesta get better over time?

A: Official information indicates that many common side effects, such as dryness, typically resolve after the completion of the course of treatment. However, regulatory documents also report that some rare or serious adverse effects may persist after discontinuation.

How should Mayesta be stored and disposed of?

How to Store and Dispose of Mayesta (Isotretinoin Capsules)

Official regulatory labeling dictates specific storage and disposal requirements to maintain the product's integrity and ensure safety.


Storage Conditions

Mayesta must be stored at controlled room temperature, specifically between 20^circ and 25 C (68^circ and 77 F). The capsules require protection from heat, moisture, and direct light; they must not be allowed to freeze. To ensure protection from light, the medicine should be kept in the original package, including storing the blister in the outer carton. This medication must always be kept out of the reach of children.

Disposal Instructions

Unused or expired Mayesta must be discarded in accordance with local regulations. The preferred method is using a medication take-back program. If a take-back program is unavailable, the capsules should be mixed with an undesirable substance (such as coffee grounds or cat litter) and placed in a sealed container before discarding in the household trash. The capsules must not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mayesta found in:

A-Z Index: